Alamar Biosciences
ALMR
26.48
-2.20
-7.67%
Alamar Biosciences
US · ALMR
#2657 by market cap
Listed 2026
26.48
-2.20
-7.67%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
About Alamar Biosciences
Alamar Biosciences, Inc. engages in developing a proteomic liquid biopsy platform and sells instruments, consumables & services for the early detection of diseases. Its products include ARGO HT system, NULISA assays for Immunology, neurology & oncology, NULISAqpcr custom assay development, technology access program and Alamar analysis solutions. The company was founded by Yuling Luo, Yiyuan Yin and Steve Chen in May 2018 and is headquartered in Fremont, CA.
- Founded
- 2018
- CEO
- Dr. Yuling Luo, PhD
- Employees
- 222
- Headquarters
- Fremont, California, United States of America
- Fiscal year end
- 12-31
- Website
- alamarbio.com
Company profile
- Exchange
- US
- Symbol
- ALMR
- Market-cap rank
- #2657
- Listing date
- 2026-04-17
- Market cap
- 1.84B
- Float cap
- 1.11B
- Shares out
- 69.48M
- Float shares
- 41.98M
Sectors & themes
Medical Devices
IPOs
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Alamar Biosciences discussion 0 comments